Teleflex (TFX)

NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$136.29-0.21%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Teleflex’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.0%

+10% or more+5%0%−5%−10% or less

10.95 → 10.95 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	583.95M
EPS	—	2.19
FY 2026 · Annual
Revenue	—	2.27B
EPS	$2.54–$2.84GAAP	7.217
Reducing revenue growth	13.4%–14.4%GAAP	—
FY 2027 · Annual
Revenue	—	2.37B
EPS	—	10.948

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce debt by $800 million using divestiture proceeds	Debt reduction and share buybacks improve financial health.	Improving	Debt reduction falls short of $800 million by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The Company completed the OEM divestiture and used proceeds to pay off $700 million Term Loan A-2 and repurchased $250 million of stock in 2026-Q2. The $1 billion share repurchase program remains active with $750 million available. Management is delivering on capital allocation by reducing debt and repurchasing shares. Delivery assessment Oct 24, 2026
EPS between $6.25 and $6.55 in 2026	A primary condition in Teleflex's published investment case. The stated target is EPS between $6.25 and $6.55.	Broken	EPS falls below $6.25 in FY26	Diluted EPS: $2.28 per share FY2026-Q2; GAAP. Published target: EPS between $6.25 and $6.55. Target period is not explicitly aligned with this observation. Source published Aug 6, 20262.28 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: aea2d659-aab3-476e-99e6-ac2cdd515e86. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full year 2026 revenue growth of 14.4% to 15.4% GAAP	A primary condition in Teleflex's published investment case. The stated target is 14.4% to 15.4% growth.	Broken	YoY revenue growth falls below 8.5% in FY26	Revenue growth: -26.96% FY2026-Q2; GAAP. Published target: 14.4% to 15.4% growth. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-26.963755 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: aea2d659-aab3-476e-99e6-ac2cdd515e86. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue growth guidance was maintained at 4.5% to 5.5% in 2025-Q4 and 2026-Q1, then reduced to 3.5% to 4.5% in 2026-Q2. Actual revenue grew 28.9% year-over-year in 2026-Q2, reflecting strong performance but management lowered guidance reflecting integration delays. The trajectory shows mixed delivery with a downward revision in guidance. Delivery assessment Oct 24, 2026
Complete strategic divestitures in second half of 2026	A supporting condition in Teleflex's published investment case. The stated target is Complete divestitures by end 2026-H2.	Intact	Divestitures not completed by end 2026-H2	1 of 1 divestitures completed (OEM sale closed 2026-08-03) vs target end 2026-H2 Teleflex completed the sale of its OEM Business to Lotus US Bidco Inc. on August 3, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The OEM divestiture was completed in 2026-Q2 for $1.5 billion with estimated after-tax proceeds of $1.25 billion. Management expects the remaining strategic divestitures to close in the second half of 2026. This priority is delivering with the OEM divestiture completed and other divestitures on track. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$10.95

$10.58 → $10.95 · observed estimates

FY2027 revenue$2.37B

$2.40B → $2.37B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$10.58	$2,399,686,050	12 / 12
2026-07-25	$10.58	$2,399,599,062	9 / 11
2026-07-26	$10.58	$2,399,599,062	9 / 11
2026-07-27	$10.58	$2,399,686,050	12 / 12
2026-07-28	$10.58	$2,399,686,050	12 / 12
2026-07-29	$10.58	$2,399,599,062	9 / 11
2026-07-30	$10.58	$2,396,551,020	13 / 13
2026-07-31	$10.58	$2,396,470,726	10 / 12
2026-08-01	$10.58	$2,396,470,726	10 / 12
2026-08-02	$10.58	$2,396,551,020	13 / 13
2026-08-03	$10.58	$2,396,551,020	13 / 13
2026-08-04	$10.58	$2,396,470,726	10 / 12
2026-08-05	$10.58	$2,396,470,726	10 / 12
2026-08-06	$10.58	$2,396,558,710	13 / 13
2026-08-08	$10.76	$2,384,368,000	13 / 12
2026-08-09	$10.87	$2,372,408,920	13 / 13
2026-08-10	$10.58	$2,396,470,726	10 / 12
2026-08-12	$10.58	$2,396,470,726	10 / 12
2026-08-13	$10.58	$2,396,470,726	10 / 12
2026-08-14	$10.58	$2,396,470,726	10 / 12
2026-08-15	$10.58	$2,396,470,726	10 / 12
2026-08-16	$10.58	$2,396,470,726	10 / 12
2026-08-17	$10.58	$2,396,470,726	10 / 12
2026-08-18	$10.58	$2,396,470,726	10 / 12
2026-08-19	$10.58	$2,396,470,726	10 / 12
2026-08-20	$10.95	$2,367,016,437	9 / 11
2026-08-21	$10.95	$2,367,016,437	9 / 11
2026-08-22	$10.95	$2,367,016,437	9 / 11
2026-08-23	$10.95	$2,367,016,437	9 / 11
2026-08-24	$10.95	$2,367,016,437	9 / 11
2026-08-25	$10.95	$2,367,016,437	9 / 11
2026-08-26	$10.95	$2,367,016,437	9 / 11
2026-08-27	$10.95	$2,367,016,437	9 / 11
2026-08-28	$10.95	$2,367,016,437	9 / 11
2026-08-29	$10.95	$2,367,016,437	9 / 11
2026-08-30	$10.95	$2,367,016,437	9 / 11
2026-08-31	$10.95	$2,367,016,437	9 / 11
2026-09-01	$10.95	$2,367,016,437	9 / 11
2026-09-02	$10.95	$2,367,016,437	9 / 11
2026-09-03	$10.95	$2,367,016,437	9 / 11
2026-09-04	$10.95	$2,367,016,437	9 / 11
2026-09-05	$10.95	$2,367,016,437	9 / 11
2026-09-06	$10.95	$2,367,016,437	8 / 11
2026-09-07	$10.95	$2,367,016,437	8 / 11
2026-09-08	$10.95	$2,367,016,437	8 / 11
2026-09-09	$10.95	$2,367,016,437	8 / 11
2026-09-10	$10.95	$2,367,016,437	8 / 11
2026-09-11	$10.95	$2,367,016,437	7 / 11
2026-09-12	$10.95	$2,367,016,437	7 / 11
2026-09-13	$10.95	$2,367,016,437	7 / 11
2026-09-14	$10.95	$2,367,016,437	7 / 11
2026-09-15	$10.95	$2,367,016,437	7 / 11
2026-09-16	$10.95	$2,367,016,437	7 / 11
2026-09-17	$10.95	$2,367,016,437	7 / 11
2026-09-18	$10.95	$2,367,016,437	7 / 11
2026-09-19	$10.95	$2,367,016,437	7 / 11
2026-09-20	$10.95	$2,367,016,437	7 / 11
2026-09-21	$10.95	$2,367,016,437	7 / 11
2026-09-22	$10.95	$2,367,016,437	7 / 11
2026-09-23	$10.95	$2,367,016,437	7 / 11
2026-09-24	$10.95	$2,367,016,437	7 / 11
2026-09-25	$10.95	$2,367,016,437	7 / 11
2026-09-26	$10.95	$2,367,016,437	7 / 10
2026-09-27	$10.95	$2,367,016,437	7 / 10
2026-09-28	$10.95	$2,367,016,437	7 / 10
2026-09-29	$10.95	$2,367,016,437	7 / 10
2026-09-30	$10.95	$2,367,016,437	7 / 10
2026-10-01	$10.95	$2,367,016,437	7 / 10
2026-10-02	$10.95	$2,367,016,437	7 / 10
2026-10-03	$10.95	$2,367,016,437	8 / 10
2026-10-04	$10.95	$2,367,016,437	8 / 10
2026-10-05	$10.95	$2,367,016,437	8 / 10
2026-10-06	$10.95	$2,367,016,437	8 / 10
2026-10-07	$10.95	$2,367,016,437	8 / 10
2026-10-08	$10.95	$2,367,016,437	8 / 10
2026-10-09	$10.95	$2,367,016,437	8 / 10
2026-10-10	$10.95	$2,367,016,437	8 / 10
2026-10-11	$10.95	$2,367,016,437	8 / 10
2026-10-12	$10.95	$2,367,016,437	8 / 10
2026-10-13	$10.95	$2,367,016,437	8 / 10
2026-10-14	$10.95	$2,367,016,514	8 / 10
2026-10-15	$10.95	$2,367,016,514	8 / 10
2026-10-16	$10.95	$2,367,016,514	8 / 10
2026-10-17	$10.95	$2,367,016,514	8 / 10
2026-10-18	$10.95	$2,367,184,556	7 / 10
2026-10-19	$10.95	$2,367,184,556	7 / 10
2026-10-20	$10.95	$2,367,184,556	7 / 10
2026-10-21	$10.95	$2,367,184,556	7 / 10
2026-10-22	$10.95	$2,367,184,556	7 / 10
2026-10-23	$10.95	$2,367,184,556	7 / 10
2026-10-24	$10.95	$2,367,184,556	7 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	9
2026-06-01	4	8
2026-07-01	5	8
2026-08-01	5	8
2026-09-01	6	8
2026-10-01	6	7

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Truist FinancialOct 14 · prior Aug 10

$150.00 → $142.00-5.3%

$0$82.50$165.00

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce debt by $800 million using divestiture proceedsDirect metric needs a verified mapping
EPS between $6.25 and $6.55 in 2026Published status: Broken
Full year 2026 revenue growth of 14.4% to 15.4% GAAPPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.0%Typical daily move · historical

Downside history

-24.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Teleflex outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a medical-device business with a mixed execution profile rather than a straightforward growth story. Its long-term thesis is intact, with robust earnings quality and strong recent performance, though management execution is volatile and the business is currently loss-making on the value measure provided.

What's priced into Teleflex

The evidence describes TFX as cheap versus peers, while also showing a 52% premium versus peers and a negative expectations gap, so the valuation picture is mixed. The market appears to recognize some business strength, but the evidence does not show high fragility in what is priced in.

What the fundamentals likely do

Near term, 2026 second-quarter revenue grew 28.9% year over year, but management lowered its 2026 revenue-growth guidance to 3.5% to 4.5%, citing integration delays. Divestitures are progressing, and proceeds have supported debt reduction and share repurchases, though recent earnings surprises have been erratic and management execution remains volatile.

What Teleflex hinges on

The multi-year view hinges on management completing the remaining divestitures and restoring confidence after the guidance reduction. Near term, another guidance cut or further labor-market weakening could weigh on the business outlook, while continued strong results from healthcare peers could support sector momentum.